KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	irinotecan + metformin Sensitive: C3 – Early Trials irinotecan + metformin Sensitive : C3	irinotecan + metformin Sensitive: C3 – Early Trials irinotecan + metformin Sensitive : C3
IDH1 mutation	Cholangiocarcinoma	IDH1 mutation	Cholangiocarcinoma	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3
IDH1 mutation	Sarcoma	IDH1 mutation	Sarcoma	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3
IDH1 mutation	Glioma	IDH1 mutation	Glioma	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3
MGMT promoter methylation	Glioblastoma	MGMT promoter methylation	Glioblastoma	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3	metformin Sensitive: C3 – Early Trials metformin Sensitive : C3
BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib + phenformin Sensitive: C3 – Early Trials trametinib + dabrafenib + phenformin Sensitive : C3	trametinib + dabrafenib + phenformin Sensitive: C3 – Early Trials trametinib + dabrafenib + phenformin Sensitive : C3
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	metformin Sensitive: D – Preclinical metformin Sensitive : D	metformin Sensitive: D – Preclinical metformin Sensitive : D
miR-17-HG overexpression + MYC positive	Lymphoma	miR-17-HG overexpression + MYC positive	Lymphoma	phenformin Sensitive: D – Preclinical phenformin Sensitive : D	phenformin Sensitive: D – Preclinical phenformin Sensitive : D
miR-17-HG expression + MYC positive	Lymphoma	miR-17-HG expression + MYC positive	Lymphoma	phenformin Sensitive: D – Preclinical phenformin Sensitive : D	phenformin Sensitive: D – Preclinical phenformin Sensitive : D
miR-17-HG deletion + MYC positive	Lymphoma	miR-17-HG deletion + MYC positive	Lymphoma	phenformin Resistant: D – Preclinical phenformin Resistant : D	phenformin Resistant: D – Preclinical phenformin Resistant : D
HSPA6 expression	Esophageal Squamous Cell Carcinoma	HSPA6 expression	Esophageal Squamous Cell Carcinoma	metformin Sensitive: D – Preclinical metformin Sensitive : D	metformin Sensitive: D – Preclinical metformin Sensitive : D
MCT1 overexpression + SLC16A3 overexpression	Multiple Myeloma	MCT1 overexpression + SLC16A3 overexpression	Multiple Myeloma	metformin + syrosingopine Sensitive: D – Preclinical metformin + syrosingopine Sensitive : D	metformin + syrosingopine Sensitive: D – Preclinical metformin + syrosingopine Sensitive : D
ROS1 amplification	Colon Cancer	ROS1 amplification	Colon Cancer	metformin + efavirenz + fluoxetine Sensitive: D – Preclinical metformin + efavirenz + fluoxetine Sensitive : D	metformin + efavirenz + fluoxetine Sensitive: D – Preclinical metformin + efavirenz + fluoxetine Sensitive : D

AMPK activator

AMPK activator

Associations(13)

Associations
(13)